Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
08/03/2020 08/04/2020 08/05/2020 08/06/2020 08/07/2020 Date
6.64(c) 6.72(c) 6.77(c) 6.76(c) 6.78(c) Last
109 144 96 943 57 590 145 465 94 129 Volume
+2.31% +1.20% +0.74% -0.15% +0.30% Change
More quotes
Financials
Sales 2020 35,0 M 41,4 M 41,4 M
Net income 2020 -22,0 M -26,0 M -26,0 M
Net cash position 2020 32,2 M 38,1 M 38,1 M
P/E ratio 2020 -8,63x
Yield 2020 -
Sales 2021 82,0 M 97,0 M 97,0 M
Net income 2021 -11,5 M -13,5 M -13,5 M
Net cash position 2021 50,1 M 59,3 M 59,3 M
P/E ratio 2021 -17,0x
Yield 2021 -
Capitalization 192 M 228 M 227 M
EV / Sales 2020 4,57x
EV / Sales 2021 1,73x
Nbr of Employees 47
Free-Float 82,3%
More Financials
Company
Poxel is a biopharmaceutical company that specializes in the development of medicines for the treatment of metabolic diseases, primarily type II diabetes. At the end of 2019, the group had a portfolio of 3 products in clinical development, including 1 in Phase III (Imeglimin for the treatment of type II diabetes and its associated pathologies) and 3 in phase II (PXL770, PXL065 and PXL007 for the treatment of... 
More about the company
Surperformance© ratings of Poxel
Trading Rating : Investor Rating : -
More Ratings
Latest news on POXEL
08/06POXEL : Corporate Presentation - English
PU
07/30POXEL : Announces Submission of Imeglimin Japanese New Drug Application for the ..
BU
07/21POXEL : Provides Corporate Update and Reports Cash and Revenue for the Second Qu..
BU
07/07POXEL : Corporate Presentation - English
PU
06/25POXEL : Announces Results from June 24, 2020 Ordinary Annual and Extraordinary G..
BU
06/25POXEL : Announces Positive Pharmacokinetic Pharmacodynamic Study Results for PXL..
AQ
06/24POXEL : Announces Positive Pharmacokinetic (PK) / Pharmacodynamic (PD) Study Res..
BU
05/28POXEL : Announces Participation in Upcoming Virtual Investor Conferences
BU
05/26Poxel Successfully Raises EUR17.7 Million in a Capital Increase
AQ
05/25POXEL : Announces Program Update and Preclinical Results on PXL770 for NASH Comb..
BU
05/25POXEL : Successfully Raises €17.7 Million in a Capital Increase
BU
05/18POXEL : Announces Notice of its Annual General Meeting to be Held on June 24, 20..
BU
05/18POXEL : Mixed general shareholder meeting
CO
04/21POXEL : Announces First Quarter 2020 Financial and Corporate Update
BU
04/21POXEL : 1st quarter earnings
CO
More news
News in other languages on POXEL
08/06POXEL : Corporate Presentation - English
07/30EN DIRECT DES MARCHES : Air Liquide, Airbus, Danone, EDF, Euronext, Hermès, F..
07/30POXEL : Announces Submission of Imeglimin Japanese New Drug Application for the ..
07/30POXEL : annonce le dépôt de la demande d'enregistrement de l'Imeglimine au Japon..
07/22Des signaux contradictoires
More news
Chart POXEL
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 17,60 €
Last Close Price 6,76 €
Spread / Highest target 211%
Spread / Average Target 160%
Spread / Lowest Target 103%
EPS Revisions
Managers
NameTitle
Thomas Kuhn Chief Executive Officer & Director
Pierre Legault Chairman
Sebastien Bolze Chief Operating Officer & Executive Vice President
Anne Renevot Chief Financial Officer & Executive Vice President
Sophie Hallakou-Bozec Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
POXEL-44.59%228
GILEAD SCIENCES, INC.5.89%86 313
VERTEX PHARMACEUTICALS24.84%71 196
REGENERON PHARMACEUTICALS65.44%65 370
WUXI APPTEC CO., LTD.73.86%38 945
GENMAB A/S53.22%23 587